MC-Val-Cit-PAB-Doxorubicin CAS:159857-70-2 is an advanced precursor for antibody-drug conjugates (ADCs), featuring a maleimide group that facilitates conjugation with thiol-containing molecules. Doxorubicin, an anthracycline antibiotic, possesses potent antineoplastic activity, making this complex a promising candidate for cancer therapy research.
Introduction to the application:
In pharmaceutical research and development, MC-Val-Cit-PAB-Doxorubicin is an essential component for designing targeted ADCs. The maleimide group allows for efficient conjugation with thiol-containing molecules, such as antibodies, while Doxorubicin’s antineoplastic properties enhance treatment efficacy. As a reagent grade compound, MC-Val-Cit-PAB-Doxorubicin is instrumental in driving the development of innovative and more effective cancer therapeutics, paving the way for improved patient outcomes.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
